PCSK9 Inhibitors | Worth It? For Whom?

June 19, 2017 – Big Pharma, insurers, and doctors engage debate over efficacy and cost; meanwhile, patients struggle to access to an expensive new class of cholesterol drugs.

Sumathi Reddy writing in the The Wall Street Journal offers a fascinating look at the tangled moral issues involved in securing patient access to ever more expensive drugs. The drugs in question—Praluent and Repatha—are the only two PCSK9 inhibitors on the market. Introduced in 2015 to reduce levels of LDL (bad) cholesterol, the drugs each cost over $14,000 a year.

Some doctors believe PCSK9 inhibitors could be a lifesaving solution for millions of heart-disease patients, especially those with a genetic disorder known as familial hypercholesterolemia (FH). In patients with FH, the liver is unable to remove excess LDL. The WSJ article details some of the difficulties these patients face in trying to gain access to the drugs,

According to the author, “Doctors and patients say getting insurance to pay for the drugs is a battle that requires countless hours, applications and appeals. Even then, the battle for insurance approval of PCSK9 inhibitors is successful less than half the time, according to several recent studies.” Of course, high copays can pose an additional barrier for those who are approved.

Health insurers, for their part, point out that there are less-expensive alternatives for most patients and that doctors are somewhat divided on the efficacy of these new drugs. Indeed, according to Sanjay Kaul, a cardiologist at Cedars-Sinai Medical Center in Los Angeles, a clinical trial of Amgen’s Repatha shows that the lower LDL “didn’t translate into a mortality benefit.”

(The author also spoke to a Dr. Baum, a big believer in PCSK9 inhibitors, who happens to have been paid as a consultant and board member for both Amgen and Sanofi/Regeneron.)

As the article notes, some health plans have entered into “value-based” contracts with drug companies, in which the drug company gives the insurer discounts on the drugs if the medicines don’t help patients lower their cholesterol levels as much as expected. We are waiting to see how those deals work out (for patients and for their self-funded employers). Click here to read more on that subject. 

Scripta recommends that our clients require pre-authorization for both Repatha and Praluent.

Read Sumathi Reddy’s piece in the Wall Street Journal: 

“When Cholesterol Drugs Cost $14,000, an Insurance Tug-of-War“


40 Grove St, Suite 270 Wellesley, MA 02482

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle


© Copyright 2020 Scripta Insights, Inc. 

Scripta™ is neither a pharmacy nor a doctor. The benefit service does not tell you what drug to take and does not participate in the drug selection process. Only your physician can determine the medications that are right for you. These alternative medications are options for less costly drugs that physicians may prescribe in place of the medications you are taking now. Scripta has reviewed your current medications only for the purpose of identifying potential cost savings for you to consider with your physician. Scripta has not analyzed the effectiveness or other therapeutic aspects of these medication alternatives. Accordingly, this report and any other forms of communication received from Scripta are not, nor should they be interpreted as, any form of treatment, drug regimen review, or provision of counseling or consultation by a prescriber, pharmacist or pharmacy. Do not stop taking your medication, change your medication, or start taking a new medication without being directed to do so by your physician and filling the prescription under the oversight of a licensed pharmacist. The alternatives set forth above may not be equivalent to your current medication, may interact adversely with your other medications, may not be indicated in light of your other conditions, may cause different or severe side effects, or may be less effective at treating your condition. Medication prices are approximate based on information provided by your pharmacy benefits manager, insurance plans, and/or employer, and may vary from pharmacy to pharmacy. Check with your insurance plan to obtain a full list of pharmacies where your prescriptions can be filled. All information herein is HIPAA protected, treated as highly confidential, and never shared with your employer.

Scripta™, Scripta Insights™ and The Best Meds at the Best Price® are registered trademarks of Scripta Insights, Inc. The contents of the site are for informational purposes only and not intended as a substitute for professional medical advice, diagnosis, or treatment. We do not recommend or endorse any specific prescription drug or pharmacy that may be mentioned herein. Reliance on any information provided by us, our affiliates, employees or others is solely at your own risk.